Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Donkena Krishna Vanaja, Michael E. Grossmann, John C. Cheville, Mozammel H. Gazi, Aiyu Gong, Jin San Zhang, Katalin Ajtai, Thomas P. Burghardt & Charles Y. F. Young. (2009) PDLIM4, An Actin Binding Protein, Suppresses Prostate Cancer Cell Growth. Cancer Investigation 27:3, pages 264-272.
Read now
Read now
Qinghua Feng, Mujun Yu & Nancy B. Kiviat. (2006) Molecular Biomarkers for Cancer Detection in Blood and Bodily Fluids. Critical Reviews in Clinical Laboratory Sciences 43:5-6, pages 497-560.
Read now
Read now
Articles from other publishers (19)
Won Kyung Kim, Adam W. Olson, Jiaqi Mi, Jinhui Wang, Dong-Hoon Lee, Vien Le, Alex Hiroto, Joseph Aldahl, Christian H. Nenninger, Alyssa J. Buckley, Robert Cardiff, Sungyong You & Zijie Sun. (2022) Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes. Nature Communications 13:1.
Crossref
Crossref
Akane Yamagishi, Yuki Ikeda, Masayoshi Ikeuchi, Ryuzaburo Yuki, Youhei Saito & Yuji Nakayama. (2020) Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. International Journal of Molecular Sciences 21:3, pages 1058.
Crossref
Crossref
Caterina Mancarella, Irene Casanova-Salas, Ana Calatrava, Maria García-Flores, Cecilia Garofalo, Andrea Grilli, José Rubio-Briones, Katia Scotlandi & José Antonio López-Guerrero. (2017) Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status. BMC Cancer 17:1.
Crossref
Crossref
Zhaoyi Chen, Travis Gerke, Victoria Bird & Mattia Prosperi. (2017) Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review. Biomedicine Hub 2:2, pages 1-15.
Crossref
Crossref
Dorothy M. K. Keefe & Emma H. Bateman. (2011) Tumor control versus adverse events with targeted anticancer therapies. Nature Reviews Clinical Oncology 9:2, pages 98-109.
Crossref
Crossref
Antonino Belfiore. 2012. Advances in Rapid Sex-Steroid Action. Advances in Rapid Sex-Steroid Action
193
212
.
Rosalyn D. Ferguson, Nyosha Alikhani, Archana Vijayakumar, Yvonne Fierz, Dara Cannata & Shoshana Yakar. 2012. Insulin-like Growth Factors and Cancer. Insulin-like Growth Factors and Cancer
105
146
.
Emine Elif Ozkan. (2011) Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Molecular and Cellular Endocrinology 344:1-2, pages 1-24.
Crossref
Crossref
Benjamin W. Turney, Gareth D.H. Turner, Simon F. Brewster & Valentine M. Macaulay. (2011) Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU International 107:9, pages 1488-1499.
Crossref
Crossref
Antonino Belfiore, Ira D. Goldfine & Roberta Malaguarnera. 2011. Insulin Resistance and Cancer. Insulin Resistance and Cancer
243
268
.
Rongshi Li, Alan Pourpak & Stephan W. Morris. (2009) Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach. Journal of Medicinal Chemistry 52:16, pages 4981-5004.
Crossref
Crossref
Amir Abbas Samani, Shoshana Yakar, Derek LeRoith & Pnina Brodt. (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews 28:1, pages 20-47.
Crossref
Crossref
Mark F. McCarty. (2016) Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy. Integrative Cancer Therapies 3:4, pages 349-380.
Crossref
Crossref
Michal Grzmil, Bernhard Hemmerlein, Paul Thelen, Stefan Schweyer & Peter Burfeind. (2003) Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up‐regulates IGF binding protein‐3, and suppresses MMP‐2 expression. The Journal of Pathology 202:1, pages 50-59.
Crossref
Crossref
H.A. Ismail, M. Pollak, H. Behlouli, S. Tanguay, L.R. Bégin & A.G. Aprikian. (2003) Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU International 92:7, pages 699-702.
Crossref
Crossref
Markus Letsch, Andrew V. Schally, Rebeca Busto, Ana M. Bajo & Jozsef L. Varga. (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proceedings of the National Academy of Sciences 100:3, pages 1250-1255.
Crossref
Crossref
Y. Lee, E. Schwarz, M. Davies, M. Jo, J. Gates, J. Wu, X. Zhang & J. R. Lieberman. (2006) Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. Journal of Orthopaedic Research 21:1, pages 62-72.
Crossref
Crossref
Luis M. Montuenga, Laura Guembe, M. Angela Burrell, M. Elena Bodegas, Alfonso Calvo, Jesús J. Sola, Pilar Sesma & Ana C. Villaro. (2003) The diffuse endocrine system: from embryogenesis to carcinogenesis. Progress in Histochemistry and Cytochemistry 38:2, pages 153-272.
Crossref
Crossref
Ruxandra Draghia-Akli, Kevin A. Hahn, Glen K. King, Kathleen K. Cummings & Robert H. Carpenter. (2002) Effects of Plasmid-Mediated Growth Hormone-Releasing Hormone in Severely Debilitated Dogs with Cancer. Molecular Therapy 6:6, pages 830-836.
Crossref
Crossref